---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000061"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:58:10.505990+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2

## Summary
- Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.
- Net loss of $112M vs $4M in Q1 2024; R&D expenses rose to $122M from $109M.
- Cash, equivalents, marketable securities $1.0B; sufficient to fund through initial pivotal readouts.
- Phase 3 PEAK-1 trial of casdatifan + cabozantinib in ccRCC expected to initiate Q2 2025.
- FDA feedback on etrumadenant supports registrational path but Arcus not pursuing Phase 3 now.

## SEC filing metadata
- accession: 0001724521-25-000061
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/0001724521-25-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/rcus-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000061
- JSON: https://secwatch.observer/filing/0001724521-25-000061.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.